Dr Jo Welton

​Dr Jo Welton

Job Title: Lecturer in Biomedical Sciences
Telephone No: + 44 (0) 29 2020 417140
Email Address: JWelton@cardiffmet.ac.uk
Room Number: D2.08


I am involved in teaching both the Biomedical Science BSc (Hons) and MSc courses. I am mainly involved in teaching MSc level biochemistry modules and research and analytical methods across both courses. I also supervise research projects for MSc and BSc.

Modules I am involved with:

  • ASF3012 - Keys Skills in Health Sciences
  • APS5016 - Analytical and Research Methods
  • APS6020 - The Biological & Laboratory Investigation of Disease
  • APS6022 - Research Project
  • MBS7000 - Medical Biochemistry
  • MBS7001 - Advanced Topics in Medical Biochemistry
  • MBS7010 - Dissertation
  • MBS7018 / MBS7023 - Research and Enterprise Strategies in Biomedical Sciences (Module Lead)


I consider my research background as cell biologist and biochemist, with my research interests centering on exploring the potential of extracellular vesicles (EVs), particularly exosomes, as a possible source of biomarkers for disease.

Exosomes are nanometre sized vesicles formed in the endocytic pathway within multivesicular bodies (MVBs). Upon fusion of the MVB with the cell membrane the exosomes contained within are released into the extracellular environment. These exosomes contain proteins, mRNA, miRNA and DNA from the secreting cell and are often enriched with proteins associated with disease, inflammation, and/or cellular stress. This makes them a potential source of multiple biomarkers for diseases, which can be obtained by minimally invasive means (from biofluids such as plasma and urine).

Exosomes as biomarkers for disease (2006-2010; 2013-present)

My most recent work has involved developing methods for the isolation of EVs from biological fluids and standardising their analysis for quality assurance. Once the isolation methodologies were optimised the proteome of these biofluid-derived EVs (plasma, urine and cerebrospinal fluid) were examined using a novel aptamer based protein arrays and analysed in silico through the use of the statistics package R. These methodologies have been used in the context of prostate cancer and multiple sclerosis biomarker discovery pilot studies. These two projects have shown the potential of both novel isolation methods for exosomes and protein analysis have the potential to identify novel disease biomarkers in follow-up studies.

Immunology Research (2011-2013)

Previous research has looked at the phenotype of peripheral blood mononuclear cells and plasma pro-inflammatory cytokines with respect to the acute phase response (APR) of osteoporosis patients and breast cancer patients undergoing aminobisphosphonate (nBP) treatment. We identified that peripheral γδ T cells and Monocytes became rapidly activated and ultimately determines the clinical severity of the APR in nBP naïve osteoporosis patients. The findings of this study may have diagnostic and prognostic implications for patients with and without malignancy as well as relevance for Vγ9/Vδ2 T-cell based immunotherapy. We also undertook a comprehensive meta-analysis of 15 randomized clinical trials patients on adjuvant therapy for breast cancer with zoledronate, identifying a significant overall survival benefit with zoledronate treatment. These new findings supported the call for zoledronate to be considered as a new standard of care in adjuvant breast cancer therapy.


  • Welton JL, Loveless S, Stone T, von Ruhland C, Robertson NP, Clayton A. (2017). Cerebrospinal fluid extracellular vesicle enrichment for protein biomarker discovery in neurological disease; multiple sclerosis. JEV. (6) 1369805 (Awaiting Impact Factor) Link: https://doi.org/10.1080/20013078.2017.1369805

  • Pathan M, Welton JL, et al. (2017). A novel community driven software for functional enrichment analysis of extracellular vesicles data. JEV. (6) 1321455 (Awaiting Impact Factor) Link: https://doi.org/10.1080/20013078.2017.1321455 

  • Welton JL, Brennan P, Gurney M, Webber JP, Spary LK, Carton DG, Falcón-Pérez JM, Walton SP, Mason MD, Tabi Z and Clayton A. (2016). Proteomics analysis of vesicles isolated from plasma and urine of prostate cancer patients using a multiplex, aptamer-based protein array. JEV. (5) 31209 (Awaiting Impact Factor) Link: http://dx.doi.org/10.3402/jev.v5.31209
  • Welton JL, JP Webber, L-A Botos, M Jones, A Clayton. (2015) Ready-made chromatography columns for extracellular vesicle isolation from plasma JEV. (4) 27269 (Awaiting Impact Factor, Citations: 17) Link: 10.3402/jev.v4.27269
  • Welton JL, S Marti, MH Mahdi, C Boobier, PJ Barrett-Lee, M Eberl. (2013) γδ T cells predict outcome in Zoledronate-treated breast cancer patients. The Oncologist. 18(8): e22-3 (Impact Factor: 4.54, Citations: 3) Link: doi: 10.1634/theoncologist.2013-0097
  • Welton JL, Morgan MP, Marti S, Stone MD, Moser B, Sewell AK, Turton J, Eberl M. (2013) Monocytes and γδ T cells control the acute phase response to intravenous zoledronate: Insights from a phase IV safety trial. J Bone Miner Res. 28(3): 464-471 (Impact Factor: 6.832, Citations: 32) Link: doi: 10.1002/jbmr.1797
  • Hayes JS*, Welton JL*, Wieling R, Richards RG. (2012) In vivo evaluation of defined polished titanium surfaces to prevent soft tissue adhesion. J Biomed Mater Res B Appl Biomater. 100(3):611-7 (*equal contribution to manuscript) (Impact Factor: 2.759, Citations: 7) Link: doi: 10.1002/jbm.b.31967
  • Welton JL, Khanna S, Giles PJ, Brennan P, Brewis IA, Staffurth J, Mason MD, Clayton A. (2010) Proteomic analysis of bladder cancer exosomes. Molecular and Cellular Proteomics. 9(6):1324-38 (Impact Factor: 7.254, Citations: 182) Link: doi: 10.1074/mcp.M000063-MCP201
  • Mitchell PJ*, Welton J*, Staffurth J, Court J, Mason MD, Tabi Z, Clayton A. (2009). Can urinary exosomes act as treatment response markers in prostate cancer? J Transl Med 7:4 (*equal contribution to manuscript) (Impact Factor: 3.93, Citations: 144) Link: doi: 10.1186/1479-5876-7-4

External Links